Temporal Interference Transcranial Alternating Current Stimulation Targeting the BNST or Amygdala for Generalized Anxiety Disorder

NCT07909200 · tracked via the Priya Life Science China tracker

Sponsor

Central South University

Phase

Not applicable

Started

2026-10-25

Last updated

2026-11-02

Condition(s) studied

Generalized Anxiety Disorder (GAD)

Investigational drug(s) / intervention(s)

Temporal Interference transcranial Alternating Current Stimulation (TI-tACS)Temporal Interference transcranial Alternating Current Stimulation (TI-tACS)Sham Temporal Interference transcranial Alternating Current Stimulation (TI-tACS)

Temporal Interference transcranial Alternating Current Stimulation (TI-tACS): Temporal Interference Transcranial Alternating Current Stimulation (TI-tACS) is a non-invasive neuromodulation technique that generates an envelope field (particularly 5 Hz) in deep brain regions, particularly the right BNST, through the interaction of two currents (2000 Hz, 2005Hz).

Temporal Interference transcranial Alternating Current Stimulation (TI-tACS): Temporal Interference Transcranial Alternating Current Stimulation (TI-tACS) is a non-invasive neuromodulation technique that generates an envelope field (particularly 5 Hz) in deep brain regions, particularly the right Amygdala, through the interaction of two currents (2000 Hz, 2005Hz)

Sham Temporal Interference transcranial Alternating Current Stimulation (TI-tACS): Sham Temporal Interference transcranial Alternating Current Stimulation will mimic the sensory experience of active stimulation without delivering effective current.

Study summary

This randomized controlled trial will use a three-arm, parallel-group design to evaluate the efficacy and safety of 5-Hz Temporal Interference transcranial Alternating Current Stimulation (TI-tACS) in adults with generalized anxiety disorder (GAD). A total of 75 participants will be randomized in a 1:1:1 ratio to receive stimulation targeting the right bed nucleus of the stria terminalis (BNST), stimulation targeting the right amygdala, or sham stimulation. Participants will receive three 20-minute sessions per day, with 1-hour intervals between sessions, for 7 consecutive days (21 sessions in total). The primary outcome is the change in Hamilton Anxiety Rating Scale (HAMA) total score from baseline to Week 1. Secondary and exploratory assessments will include clinical symptoms, intolerance of uncertainty and related cognitive characteristics, treatment tolerability, adverse events, and EEG and MRI measures. Follow-up assessments will be conducted at Week 1, Week 4, and Week 8 from baseline to assess the durability of clinical effects and safety.

Eligibility

Sex

ALL

Min age

18 Years

Max age

55 Years

Healthy volunteers

Inclusion Criteria: 1. Aged 18 to 55 years, inclusive, of any sex; 2. Diagnosis of generalized anxiety disorder (GAD) according to DSM-5 criteria, assessed by trained researchers using the Structured Clinical Interview for DSM-5 (SCID), without psychotic features; 3. Hamilton Anxiety Rating Scale (HAMA) total score of 14 or higher at screening; 4. Has completed at least junior high school education and has sufficient hearing, reading, writing, and comprehension abilities to complete study assessments; 5. Is willing and able to provide written informed consent and comply with study visits, treatment procedures, laboratory tests, and other study requirements. Exclusion Criteria: 1. Participants with a current or previous diagnosis of a major psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), such as schizophrenia spectrum and other psychotic disorders or bipolar and related disorders; 2. Pregnancy or lactation; 3. Neurologic disorders or serious systemic diseases (e.g., thyroid disease, lupus erythematosus, diabetes, hepatic or renal impairment, active infection, major trauma); 4. History of significant head injury or coma; 5. Received any standardized neuromodulation therapy targeting the nervous system within the past 6 months before enrollment, including but not limited to electroconvulsive therapy (ECT), deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), or vagus nerve stimulation (VNS); 6. Suspected or confirmed history of alcohol or substance dependence; 7. Current severe suicidal ideation or recent suicide attempt; 8. Current participation in another clinical trial or recent use of prohibited psychotropic medications; 9. Positive urine drug screening or abnormal thyroid function tests; 10. Contraindications to magnetic resonance imaging (MRI) or electroencephalography (EEG); 11. Inability to provide fully informed consent.

Primary outcome measure(s)

Change in Hamilton Anxiety Rating Scale (HAMA) Total Score From Baseline to Week 1 — Baseline and Week 1
Anxiety severity will be evaluated using the Hamilton Anxiety Rating Scale (HAMA), a clinician-administered instrument comprising 14 items. Total scores range from 0 to 56, with higher scores indicating more severe anxiety symptoms. The outcome is the change in HAMA total score from baseline to Week 1.

Trial sites (4)

Facility	City	Region
Neuropsychiatric Prevention and Treatment Hospital of Fuzhou Second General Hospital	Fuzhou	Fujian
Brain Hospital of Hunan Province (Hunan Second People's Hospital)	Changsha	Hunan
Second Xiangya Hospital of Central South University	Changsha	Hunan
Jiangsu Yangzhou Wutaishan Hospital	Yangzhou	Jiangsu

More Central South University trials in China

Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients Recruiting

Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia Recruiting

tACS for Working Memory in Schizophrenia Recruiting

Clinical Study of Individualized Vancomycin Dosing Based on Population PK Model Recruiting

Transcranial Alternating Current Stimulation to Enhance Mindfulness Therapy in Generalized Anxiety Disorder Starting soon

Other trials for the same condition

Multimodal Cohort Study of Generalized Anxiety Disorder Starting soon

Transcranial Alternating Current Stimulation to Enhance Mindfulness Therapy in Generalized Anxiety Disorder Starting soon

Acupuncture for Generalized Anxiety Disorder Starting soon

Clinical Efficacy and Mechanism of rTMS Based on dlPFC in the Intervention of Generalized Anxiety Disorder With Insomnia Enrolling by invitation

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07909200 on ClinicalTrials.gov ↗ ← All trials in China